aGVHD

(redirected from Acute Graft Versus Host Disease)
Also found in: Medical.
AcronymDefinition
aGVHDAcute Graft Versus Host Disease
References in periodicals archive ?
TEMCELL is already approved for the treatment of acute graft versus host disease, and was the first allogeneic cellular medicine to receive full regulatory approval in Japan.
MELBOURNE, Australia, September 20, 2018 - Mesoblast Limited (MESO) announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease (aGVHD) treated with Mesoblast's Phase 3 product candidate remestemcel-L, an allogeneic mesenchymal stem cell product candidate.
MELBOURNE, Australia, September 20, 2018 -- Mesoblast Limited (MESO) announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease (aGVHD) treated with Mesoblast's Phase 3 product candidate remestemcel-L, an allogeneic mesenchymal stem cell product candidate.
Osiris Therapeutics, Inc., Columbia, MD, announced that while preliminary results for two Phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD) showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, neither trial reached its primary endpoint.
Fungal infection and acute graft versus host disease were suspected.
Mesoblast Chief Executive Dr Silviu Itescu stated: 'It is pleasing to see the growth in revenues achieved by our Japanese partner in the treatment of acute graft versus host disease in the first three years post launch.
Based on results from an investigator-initiated trial in Japan, JCR intends to seek label extension for Temcell in Japan beyond its existing approval for the treatment of acute graft versus host disease. Under the expanded License Agreement covering EB, Mesoblast has provided JCR with access to its patent portfolio for the use of mesenchymal stem cells in wound healing.
(NovaQuest) for the continued development and commercialization of its allogeneic product candidate remestemcel-L (MSC-100-IV) for children with steroid refractory acute Graft versus Host Disease (aGVHD).
Osiris Therapeutics, Inc., Columbia, MD, announced it has completed patient enrollment in its Phase III pivotal trial evaluating Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease (GvHD), a life threatening complication after bone marrow transplantation.
The trial ("An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease") recruited adults who received an allogeneic haematopoietic stem cell transplant (HSCT) to treat a hematological (blood) disorder, and were subsequently diagnosed with steroid-resistant Grade II-IV GvHD.
Mesoblast announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV in children with steroid-refractory acute Graft versus Host Disease were presented at the 2018 International Society for Cell and Gene Therapy plenary breakout session held in Boston last week.
Full browser ?